Table 2.
Assessments of sweat productiona
| ≥ 9 to ≤ 16 y | > 16 y | |||
|---|---|---|---|---|
| Vehicle n = 19 | GT n = 25 | Vehicle n = 215 | GT n = 438 | |
| Absolute change from baseline at Week 4, mg/5 min | ||||
| Mean (SD) | −77.8 (110.6) | −67.9 (142.6) | −93.3 (141.9) | −109.9 (210.5) |
| Median | −53.7 | −64.2 | −62.0 | −80.6 |
| Percent change from Baseline at Week 4, mg/5 min | ||||
| Mean (SD) | −42.7 (38.2) | −60.1 (49.3) | −41.6 (47.9) | −56.2 (55.0) |
| Median | −55.3 | −75.4 | −54.1 | −74.2 |
| Proportion of patients with ≥ 50% reduction at Week 4, % | 54.8 | 79.9 | 53.0 | 74.3 |
Intent‐to‐treat population.
P‐values not calculated as these comparisons were post hoc and not designed or powered to detect differences; multiple imputation (MCMC) was used to impute missing values.
GT, topical glycopyrronium tosylate; MCMC, Markov chain Monte Carlo; SD, standard deviation.
a
Gravimetrically measured.